Production (Stage)
Capricor Therapeutics, Inc.
CAPR
$12.38
$0.605.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -35.92% | -11.55% | 65.33% | 187.15% | 389.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -35.92% | -11.55% | 65.33% | 187.15% | 389.30% |
| Cost of Revenue | 44.87% | 37.10% | 38.53% | 54.44% | 63.72% |
| Gross Profit | -216.04% | -145.77% | -18.38% | 12.46% | 32.06% |
| SG&A Expenses | 26.12% | 16.08% | 15.19% | 15.91% | 19.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.16% | 31.63% | 32.20% | 43.13% | 49.65% |
| Operating Income | -118.97% | -76.78% | -17.13% | 1.55% | 12.95% |
| Income Before Tax | -126.48% | -81.57% | -16.64% | 4.38% | 16.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -126.48% | -81.57% | -16.64% | 4.38% | 16.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -126.48% | -81.57% | -16.64% | 4.38% | 16.07% |
| EBIT | -118.97% | -76.78% | -17.13% | 1.55% | 12.95% |
| EBITDA | -123.23% | -78.80% | -16.32% | 3.14% | 14.95% |
| EPS Basic | -62.09% | -37.47% | 7.86% | 20.23% | 25.01% |
| Normalized Basic EPS | -61.50% | -37.22% | 7.74% | 20.15% | 24.96% |
| EPS Diluted | -62.09% | -37.47% | 7.86% | 20.23% | 25.01% |
| Normalized Diluted EPS | -61.50% | -37.22% | 7.74% | 20.15% | 24.96% |
| Average Basic Shares Outstanding | 37.03% | 31.51% | 25.00% | 19.47% | 14.12% |
| Average Diluted Shares Outstanding | 37.03% | 31.51% | 25.00% | 19.47% | 14.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |